Citation Information :
Lutfi M, Dewanto A, Widad S, Taufiqurrachman I, Kusumanto A, Pangastuti N, Silawani S. Expression of GnRH Receptor Type-II Correlates with Proliferation Activity in Endometriosis. Int J Infertil Fetal Med 2022; 13 (2):37-41.
Background: Global estimated prevalence of endometriosis is about 10 to 15% of women in reproductive age. This chronic inflammatory ectopic endometrium causes pain symptoms and is also attributed to infertility problems. Even though advances in endometriosis management have been developed, cumulative recurrence rate of endometriosis is still as high as 55% after 5 years of therapy with GnRH agonist. Therefore, further investigations are continuously needed to improve treatment outcome in endometriosis, especially through better understanding of the disease pathophysiology.
Methods: This cross-sectional study was aimed to describe the expression of GnRH receptor type-II (GnRHR-II) with immunohistochemical staining. Semiquantitative analysis of protein expression was performed with histological scoring (H-score). Moreover, the expression level of GnRHR-II was then compared to Ki-67 protein expression, a marker of cell proliferation.
Results: We found a positive correlation between GnRHR–II expression with Ki–67 protein (Pearson correlation score 0.56, 95% CI: 0.15–0.80, p = 0.01). Interestingly, our results also found that the expression of GnRHR–II was also significantly higher in groups of subjects with larger endometriosis tissue size (p = 0.02).
Conclusion: Our study showed an evidence of extrapituitary expression of GnRH receptor type-II. Endometriosis consistently expressed GnRHR-II and might play important role in the regulation of proliferation. Our results may trigger further explorations of GnRH receptor-targeted therapy that selectively inhibit proliferation pathway.
Macer ML. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am J 2012;39(4):535–549. DOI: 10.1016/j.ogc.2012.10.002
Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–519. DOI: 10.1016/j.fertnstert.2012.06.029
Hogg S, Vyas S. Endometriosis update. Obstet Gynaecol Reprod Med 2018;28(3):61–69. DOI: 10.1016/j.ogrm.2017.12.003
Magon N. Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab 2011;15(4):261–267. DOI: 10.4103/2230-8210.85575
Meresman GF, Vighi S, Buquet RA, et al. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000;74(4):760–766. DOI: 10.1016/s0015-0282(00)01522-3
Falcone T, Flyckt-Rebecca R. Clinical management of endometriosis. Obstet Gynecol 2018;131(3):557–571. DOI: 10.1097/AOG.0000000000002469
Cheung LT, Wong AST. Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 2008;275(22):5479–5495. DOI: 10.1111/j.1742-4658.2008.06677.x
Fister S, Günthert AR, Emons G. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 2007;67(4)1750–1756. DOI: 10.1158/0008-5472.CAN-06-3222
Huang F, Wang H, Zou Y, et al. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int J Clin Exp Pathol 2013;6(11):2487–2496.
Pezzilli R, Partelli S, Cannizzaro R, et al. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): a systematic review. Adv Med Sci 2016;61(1):147–153. DOI: 10.1016/j.advms.2015.10.001
Pyo J S, Kang G, Sohn JH. Ki-67 labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: a systematic review and meta-analysis. Int J Biol Markers 2016;31(2):e204–e210. DOI: 10.5301/jbm.5000183
Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma 2018;127(2):175–186. DOI: 10.1007/s00412-018-0659-8
Eisenberg VH, Weil C, Chodick G, et al. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG 2018;125(1):55–62. DOI: 10.1111/1471-0528.14711